CAR T-Cell trial for rare lymphoma halted after just one patient
NCT ID NCT06912529
First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 29 times
Summary
This study tested a CAR T-cell therapy called axicabtagene ciloleucel in people with a rare type of lymphoma (PMBCL) that came back or didn't respond to initial treatment. The goal was to see if it could make the cancer disappear. However, the study was stopped early and only enrolled one person, so we have very limited information from it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA REFRACTORY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Medizinische Klinik A Hämatologie, Hämostaseologie, Onkologie und Pneumologie Universitätsklinikum Münster
Münster, 48149, Germany
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.